A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck
Paola Pinnarò, F. Cognetti(Sapienza University of Rome), Michèle Milella(National Cancer Institute), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Cecilia Cercato, Diana Giannarelli(Agostino Gemelli University Polyclinic), F. Ambesi Impiombato, F Marzetti, Paolo Carlini(National Cancer Institute)
Cited by 22
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606